DS-1594 has demonstrated high antileukemic activity in preclinical studies and is being clinically evaluated in R/R NPM1 or KMT2A AML and ALL in combination with chemotherapy—mini-HCVD, VEN, or AZA. The gene discussed is NPM1; the disease is acute myeloid leukemia.